Tejas Savant

What fraction of MABs typically require these chronic NHP studies and what fraction were getting an FDA waiver?

How are you thinking about the time line? I know you mentioned sort of a relatively quick turnaround

Any cancellation payment benefit in the fourth quarter? Do you expect one to come through in 2025?

whether there's any step you can take proactively over the next twelve months to further de-risk your supply chain there

Just wondering beyond tariffs in China, how to think about the 60 bps haircut?

Can you just provide some context and the degree to which that that's unlocking some conversations for you

how much of Hologic's OUS revenue is made in the US and how much of US revenue was dependent on manufacturing overseas

any comments on the stranded costs associated with the mega trial that you said is now pushed to 2026

can you just share some color on follow-up conversations with other pharma companies about the possibility of similar deals

One of the benefits you had highlighted in terms of bringing Ambry in-house is that it gives you a West Coast lab.